Trial · NCT07101471
Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation
NCT07101471, Completed, NanoAlvand
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation. Trials, record NCT07101471. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07101471
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation
- NCT number
- NCT07101471
- Status
- Completed
- Enrollment
- 296 participants, actual
- Lead sponsor
- NanoAlvand
- Conditions
- Alopecia Totalis/Universalis, Alopecia Areata(AA)
- Interventions
- Tofacitinib
- First posted
- 2025-08-03
- Last updated
- 2025-08-07
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety assessment | Study period ( Up to 6 months) | Safety assessment, including the incidence of AEs. All AEs are classified based on the Medical Dictionary for Regulatory Activities (MedDRA Desktop Browser 4.0 Beta) terms as System Organ Class (SOC) and Preferred Term (PT). All the reported events are graded according to the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0). Moreover, seriousness of AEs is assessed according to International Council for Harmonisation (ICH-E2B) guidelines. The causality relation is assessed based on the World Health Organization (WHO) criteria. |
| Secondary | The percentage of change from baseline in the Severity of Alopecia Tool (SALT) Score | Study period (up to 6 months) | Severity of Alopecia Tool (SALT) Score is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). |
| Secondary | The frequency of relapse disease (Patchy or complete scalp hair loss). | Study period (up to 6 months) | |
| Secondary | The frequency and proportion of participants achieved greater or equivalent to one grade improvement in eyelash/ eyebrow scores | Study period (up to 6 months) | It is a 4-point scale that is used to assess the severity of eyebrow and eyelash hair loss in Alopecia, with the scale ranging from 0 to 3. The score of 0 equals to worth case, and the score of 3 indicates normal. |
| Secondary | Change in Dermatology Life Quality Index Total Score (DLQI) | Study period (up to 6 months) | Dermatology Life Quality Index Total Score (DLQI) is a questionnaire that ranges from 0 to 30. Higher scores indicate a greater negative impact on quality of life. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07101471
GET https://conductscience.org/api/trials/v1/NCT07101471/registered